Fifty-three clinical isolates of Klebsiella and fifty-one clinical isolates of Pseudomonas aeruginosa, twenty-six of which were carbenicillin-(CARB) resistant, were tested for susceptibility to mezlocillin (MEZ), azlocillin (AZL), and piperacillin (PIP), both alone and in combination with tobramycin (TOB) using the microtiter broth diluent method and an inoculum density of 1o6 CFU/ml. The Klebsiella were highly resistant to TOB, MEZ, and PIP (MICg: 8, > 256, > 128 ,sg/ml, respectively). Synergy was demonstrated in 53 percent (PIP/TOB) and 51 percent (MEZ/TOB). An indifferent response was observed in 47 percent (PIP/TOB) and 49 percent MEZ/TOB of the Klebsiella. PIP, MEZ, and AZL in combination with TOB showed synergism against CARB-resistant Pseudomonas in less than 10 percent of the strains tested. Synergy could be demonstrated against CARB-susceptible Pseudomonas with the combinations PIP/TOB, AZL/TOB, and MEZ/TOB in 12 percent, 12 percent, and 24 percent, respectively, of the twenty-five strains tested. Indifferent effects were observed in 84 percent, 88 percent, and 76 percent, respectively, of these same CARB-susceptible strains. These data suggest that there is no significant difference in the incidence of synergy with these new penicillins and tobramycin against either Pseudomonas or Klebsiella.
INTRODUCTION
Aminoglycosides, combined with semisynthetic penicillins, are the most widely studied antibiotic combinations for use against gram-negative bacilli, the major cause of serious sepsis in immunocompromised patients. Klebsiella and Pseudomonas represent two of the most significant pathogens in this patient population. The use of two or more antimicrobial agents for empiric therapy of such infections has become common in clinical practice [15] and is based on the hope, suggested by in vitro studies, that the drugs may interact synergistically to inhibit infecting pathogens. There are data from both animal and human trials that indicate improved clinical efficacy of synergistic antibiotic combinations [1, 2, 14] .
New broad-spectrum penicillin derivatives have been synthesized which have potent activity against both Klebsiella and Pseudomonas. Indications for use of these agents are unclear. Piperacillin and azlocillin have enhanced activity against Pseudomonas, while piperacillin and mezlocillin have enhanced activity against Klebsiella compared to carbenicillin and ticarcillin. A critical parameter in the therapy of infections with Pseudomonas is the presence of synergy. This report compares the in vitro activity of three recently introduced semisynthetic penicillins (azlocillin, mezlocillin, and piperacillin) alone and in combination with the aminoglycoside, tobramycin, against clinical isolates of Klebsiella species and of Pseudomonas aeruginosa to see of there is a clear advantage with respect to synergy for any of the penicillins. Several investigators have reported that azlocillin shows reduced efficacy against active f3-lactamase producing strains such as Klebsiella [4, 5] ,ug), piperacillin (100 ,g), and tobramycin (10 ug) impregnated discs. The diameters of zones of inhibition for all discs fell within normal ranges, confirming the quality of the solid medium.
MICs, minimum bactericidal concentrations (MBCs), and synergy were determined in microtiter plates with 96 U-shaped wells (Dynatech, Alexandria, VA) containing the antibiotics diluted in Mueller-Hinton broth (MHB). For the MICs, 100 ,ul of twofold serial dilutions of each antibiotic were added to each well. One well in each row contained only MHB to serve as an inoculation/growth control. Bacteria were grown overnight, then diluted in fresh broth to a density of approximately 1 x 108 CFU/ml, as determined with a spectrophotometer. A semiautomatic inoculator (Dynatech, Alexandria, VA) was used to deliver 1 x 105 CFU (1 x 106 CFU/ml) to each well (final concentration: 1 x 106 CFU/ml). The MIC was taken as the lowest concentration of drug with no visible growth after 18 hours of incubation at 370C. MBC data were obtained by inoculating Mueller-Hinton agar plates with an aliquot (1.5 ul) from each well of the MIC plate followed by incubation at 370C for 48 hours.
No growth was required to define the MBC (>99.9 percent killing). Thus in the absence of killing, an aliquot would contain at least 1.5 x 103 CFUs. At 99.9 percent killing this aliquot would contain 1.5 CFUs which would be detectable by agar plating.
Antibiotic synergy testing employed the same microtiter broth method described above except that dilutions of tobramycin were placed horizontally in the trays, while those of each penicillin were placed vertically, resulting in a checkerboard array of drug combinations. The concentrations chosen for each drug insured that a range from one-eighth to two times the MIC for all but very resistant strains was included. The same inoculum was delivered to each well, one well per row serving as drug-free control. After incubation at 370C for 24 hours, the lowest concentration of drugs showing no visible growth was taken as the best combination. Synergy Criteria Synergy data were evaluated using published methods [8, 13] by which the fractional inhibitory concentrations (FICs) and FIC indexes (FIXs) were calculated. The FIC for a single antibiotic was determined as the ratio of the MIC of that drug in combination, divided by the MIC when used alone. Thus, two FICs were calculated for each effective combination. The FIX was calculated as the numerical sum of the two FICs for a given combination. The following criteria were used: FIX less than or equal to 0.5, synergy; FIX greater than 0.5 but less than or equal to 2.0, indifferent effects; FIX greater than 2.0, antagonism. Typical equations for these calculations are shown:
MICX in combination x MICX alone FIX = FICX + FICy RESULTS Figure 1 shows the cumulative distribution of the MICs of bacteria tested against the semisynthetic penicillins. In each case, carbenicillin-susceptible Pseudomonas were slightly more susceptible than the carbenicillin-resistant strains. Azlocillin and piperacillin appeared more active against Pseudomonas than mezlocillin, and piperacillin demonstrated more activity against the carbenicillin-resistant Pseudomonas than either of the other two drugs. The activities of mezlocillin and piperacillin against Klebsiella appeared to be similar.
The MICs and MBCs which were effective against 50 percent and 90 percent of the Klebsiella and Pseudomonas strains tested are shown in Table 1 . As can be seen, some strains of Klebsiella were highly resistant to both mezlocillin and piperacillin, the MIC90s exceeding the highest drug concentrations used. The MIC90 data for azlocillin, mezlocillin, and piperacillin against the two groups of Pseudomonas show that these drugs have similar anti-pseudomonal activities within groups: a twofold range for carbenicillin-resistant Pseudomonas (64-128 ,ug/ml); a fourfold range for carbenicillin-susceptible Pseudomonas (8-32 ,u/ml). Pseudomonas strains resistant to carbenicillin show higher MICs for the three semisynthetic penicillins than those of the carbenicillin-susceptible strains. organisms. Antagonism was observed in three strains of carbenicillin-resistant Pseudomonas tested with azlocillin-tobramycin, and in one strain of carbenicillin-susceptible Pseudomonas using piperacillin-tobramycin. DISCUSSION Heineman and Lofton [9] tested the in vitro response of Pseudomonas to penicillinaminoglycoside combinations and concluded that an organism's MIC for an individual drug gave no hint of its response to drug combinations, and that no particular combination of drugs could be used as a screen for other combinations. With this unpredictability assumed, this investigation was designed to determine the in vitro efficacy of tobramycin combined with each of three new semisynthetic penicillins. This study was designed to use a high inoculation density (1 x 106 CFU/ml) [5] , to include carbenicillin-resistant organisms, and to adhere to strict synergy criteria in an attempt to evaluate these drugs under "most difficult" conditions of in vitro testing.
The analytical scheme used to assess synergy employs ratios and sums of ratios of drug concentrations. Investigators using this method have cited synergism with FIXs ranging from 0.3 to 0.75 [10, 13] . Using the less strict criteria (FIX less than or equal to 0.75), the incidence of synergism in this study would be considerably increased. However, the criteria used in this report (FIX less than or equal to 0.5) allowed direct comparison of data to previous reports by authors defining synergy as a fourfold reduction of the MICs of both drugs in a combination [1,3,1 11 . In fact, when our data were calculated using a fourfold reduction of the MIC for both drugs as the synergy criteria, the results were identical.
Azlocillin, mezlocillin, and piperacillin when combined with tobramycin were shown in this study to have similar synergistic activities. Other investigators report higher levels of synergism (range: 32-100 percent) for penicillin-aminoglycoside pairs [3, 10, 12] , particularly piperacillin-gentamicin [3, 6] . Although differences in technique (e.g., test method, inoculum density, analysis criteria) may account for variability, penicillinase activity (or lack of it) is also important in the response of any individual strain. Other investigators have used f-lactamase producing and nonproducing organisms when studying penicillin-derived drugs and have reported multi-modal distributions of MICs with penicillin-derived drugs [5, 12] , suggesting sub-populations of destructive enzyme producers. The trimodal distribution of Kleb-siella MICs (Fig. 1 ) may reflect the presence of fl-lactamase production in some strains analyzed in this study. Also it has recently been shown [7] that selected semisynthetic penicillins when incubated with Enterobacteriaceae species are often inactivated after seven hours, presumably due to 3-lactamase activity. The clinical significance of this inactivation is not clear.
These data do not demonstrate an advantage in the amount of synergy achieved with any of the combinations tested. Since it has been shown that the presence of antibiotic synergy represents an important parameter in predicting a positive response in Pseudomonas infections, these data may suggest there will be no clear advantage of any one of these combinations over another.
